IP Library Granted Patent US 9,446,131
Granted Patent B2
US 9,446,131 · App. 14/974,502 · Granted Sep 20, 2016

Topical compositions and methods for making and using same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,446,131
App. No.
14/974,502
Granted
Sep 20, 2016
Kind
B2
Abstract

The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.

Claims (17)

1. A method of treating atopic dermatitis in a patient in need thereof, comprising administering to a patient in need thereof a topical gel composition comprising about 0.025 wt % fluticasone, or a pharmaceutically acceptable salt or ester thereof, about 18 to about 20 wt % propylene glycol, about 1.5 wt % to about 2.0 wt % hydroxyethyl cellulose, from about 3 wt % to about 8 wt % Polysorbate 20, from about 1 wt % to about 3 wt % of a glycol ether solubilizing agent, and optionally one or more of: a diluent, a pH adjuster, a chelating agent, a preservative, a fragrance, and a coloring agent.

2. The method according to claim 1 , wherein the topical gel composition comprises about 1.75 wt % hydroxyethyl cellulose, about 5 wt % Polysorbate 20, about 1.5 wt % diethylene glycol monoethylether, water, 0.02 wt % ethylenediaminetetracetic acid (EDTA) or a salt thereof, and optionally a preservative, a pH adjuster, a fragrance, and a coloring agent.

3. The method according to claim 2 , wherein the fluticasone or pharmaceutically acceptable salt or ester thereof is fluticasone propionate.

4. The method according to claim 2 , wherein the preservative is benzyl alcohol present in an amount of about 1.0 wt %.

5. The method according to claim 1 , wherein the topical gel composition is administered to an affected area of said patient in an amount sufficient to cover the affected area plus a margin of healthy skin or tissue surrounding the affected area.

6. The method according to claim 5 , wherein the topical gel composition is administered to the affected area of said patient once or twice per day.

7. The method according to claim 5 , wherein the topical gel composition is administered to the affected area of said patient twice per day.

8. The method according to claim 5 , wherein the topical gel composition is administered to the affected area of said patient from 1 week to 4 weeks.

9. The method according to claim 8 , wherein the topical gel composition is administered to the affected area of said patient for 1 week.

10. The method according to claim 8 , wherein the topical gel composition is administered to the affected area of said patient for 2 weeks.

11. The method according to claim 8 , wherein the topical gel composition is administered to the affected area of said patient for 3 weeks.

12. The method according to claim 8 , wherein the topical gel composition is administered to the affected area of said patient for 4 weeks.

13. The method according to claim 5 , wherein the amount of topical gel composition administered is from about 1 gram to about 8 grams.

14. The method according to claim 13 , wherein the amount of topical gel composition administered is from about 1 gram to about 4 grams.

15. The method according to claim 13 , wherein the amount of topical gel composition administered is from about 2 grams to about 5 grams.

16. The method according to claim 13 , wherein the amount of topical gel composition administered is from about 2 grams to about 7 grams.

17. The method according to claim 13 , wherein the amount of topical gel composition administered is from about 3 grams to about 8 grams.

Assignments (8)
SECURITY INTEREST Recorded Mar 23, 2026
From: LEGACY PHARMA INC. SEZC
To: ROOSTER LP
Reel/Frame 074151/0761 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2025
From: SEBELA IRELAND LIMITED
To: LEGACY PHARMA INC.
Reel/Frame 070028/0472 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2019
From: SEBELA INTERNATIONAL BERMUDA LIMITED
To: SEBELA IRELAND LIMITED
Reel/Frame 049791/0116 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2018
From: SEBELA INTERNATIONAL LIMITED
To: SEBELA INTERNATIONAL BERMUDA LIMITED
Reel/Frame 046200/0934 →
RELEASE OF SECURITY INTEREST Recorded May 18, 2018
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS ADMINISTRATIVE AGENT
To: SEBELA INTERNATIONAL LIMITED
Reel/Frame 047506/0893 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 23, 2016
From: MERZ PHARMACEUTICALS, LLC
To: SEBELA INTERNATIONAL LIMITED
Reel/Frame 040411/0407 →
SECURITY INTEREST Recorded Nov 21, 2016
From: SEBELA INTERNATIONAL LIMITED
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 040394/0723 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2015
From: HARDAS, BHUSHAN; DALTON, DONNA; SCHEPPLER, PETRA; BUCH, ANJA; BODERKE, PETER
To: MERZ PHARMACEUTICALS, LLC
Reel/Frame 037348/0164 →